Contact
searchSearch
HMP Global
Login

Small-Cell Lung Cancer Specialty Channel

Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
Quiz
Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC
12/17/2025
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed...
12/17/2025
Oncology
News
Durvalumab Plus Chemotherapy Shows Real-World Activity in Extensive-Stage SCLC
12/17/2025
Stephanie Holland
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b...
12/17/2025
Oncology
News
Adding Pembrolizumab to First-Line Chemotherapy Fails to Improve Survival in Extensive SCLC
12/16/2025
Stephanie Holland
Results from the phase 2 REACTION trial demonstrate that the addition of pembrolizumab to first-line platinum-etoposide does not improve survival among chemo-sensitive patients with extensive small cell lung cancer.
Results from the phase 2 REACTION trial demonstrate that the addition of pembrolizumab to first-line platinum-etoposide does not improve survival among chemo-sensitive patients with extensive small cell lung cancer.
Results from the phase 2...
12/16/2025
Oncology
Quiz
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
12/10/2025
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following...
12/10/2025
Oncology
News
Consolidative Thoracic Radiotherapy Shows Limited Clinical Benefit in Extensive-Stage SCLC
12/10/2025
Stephanie Holland
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the...
12/10/2025
Oncology

News

News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Durvalumab Plus Chemotherapy Shows Real-World Activity in Extensive-Stage SCLC
12/17/2025
Stephanie Holland
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b...
12/17/2025
Oncology
News
Adding Pembrolizumab to First-Line Chemotherapy Fails to Improve Survival in Extensive SCLC
12/16/2025
Stephanie Holland
Results from the phase 2 REACTION trial demonstrate that the addition of pembrolizumab to first-line platinum-etoposide does not improve survival among chemo-sensitive patients with extensive small cell lung cancer.
Results from the phase 2 REACTION trial demonstrate that the addition of pembrolizumab to first-line platinum-etoposide does not improve survival among chemo-sensitive patients with extensive small cell lung cancer.
Results from the phase 2...
12/16/2025
Oncology
News
Consolidative Thoracic Radiotherapy Shows Limited Clinical Benefit in Extensive-Stage SCLC
12/10/2025
Stephanie Holland
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the...
12/10/2025
Oncology
News
Escalating Thoracic Radiotherapy Dose May Improve Survival Without Added Toxicity in Limited-Stage Small-Cell Lung Cancer
11/24/2025
Stephanie Holland
Results from a phase 2 study demonstrated that accelerated hyperfractionated thoracic radiotherapy shows favorable long-term efficacy and safety among patients with limited-stage small-cell lung cancer.
Results from a phase 2 study demonstrated that accelerated hyperfractionated thoracic radiotherapy shows favorable long-term efficacy and safety among patients with limited-stage small-cell lung cancer.
Results from a phase 2 study...
11/24/2025
Oncology
FDA Approval
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
11/19/2025
Stephanie Holland
Based on results from the phase 3 DeLLphi-304 trial, the FDA has approved tarlatamab for the treatment of patients with extensive-stage small cell lung cancer who experience disease progression on or after platinum-based chemotherapy.
Based on results from the phase 3 DeLLphi-304 trial, the FDA has approved tarlatamab for the treatment of patients with extensive-stage small cell lung cancer who experience disease progression on or after platinum-based chemotherapy.
Based on results from the phase...
11/19/2025
Oncology

Interactive Features

Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology
Quiz
Evaluating Pembrolizumab Plus Chemotherapy in Extensive SCLC
12/17/2025
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed to assess the addition of pembrolizumab to first-line platinum-etoposide in chemo-sensitive patients with extensive-stage small cell lung cancer. Which of the following best summarizes the efficacy findings?
The phase 2 REACTION trial aimed...
12/17/2025
Oncology
Quiz
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
12/10/2025
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following statements best reflects the efficacy outcomes that supported conversion of tarlatamab’s accelerated approval to traditional approval for previously treated ES-SCLC in the phase 3 DeLLphi-304 trial?
Which of the following...
12/10/2025
Oncology
Quiz
Tarlatamab for Extensive-Stage Small Cell Lung Cancer
11/24/2025
Based on results from the phase 3 DeLLphi-304 trial, the FDA has granted traditional approval to tarlatamab for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Which of the following statements best summarizes...
Based on results from the phase 3 DeLLphi-304 trial, the FDA has granted traditional approval to tarlatamab for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Which of the following statements best summarizes...
Based on results from the phase...
11/24/2025
Oncology
Quiz
Optimal Olaparib Dose Added to Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer
10/29/2025
Do you know the optimal olaparib dose in addition to thoracic radiation therapy for patients with extensive-stage small cell lung cancer? Test your knowledge with our quick quiz!
Do you know the optimal olaparib dose in addition to thoracic radiation therapy for patients with extensive-stage small cell lung cancer? Test your knowledge with our quick quiz!
Do you know the optimal olaparib...
10/29/2025
Oncology
Quiz
Atypical Characteristics of Small Cell Lung Cancer
09/18/2025
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
Dr Fawzi Abu Rous discussed the...
09/18/2025
Oncology
Quiz
Potential Shifts in Treatment for Patients With ES-SCLC
08/06/2025
In the phase 2 REBORN trial, which drug regimen was administered alongside durvalumab, and what does this suggest about the study’s approach to enhancing standard care? Test your knowledge with our quiz!
In the phase 2 REBORN trial, which drug regimen was administered alongside durvalumab, and what does this suggest about the study’s approach to enhancing standard care? Test your knowledge with our quiz!
In the phase 2 REBORN trial,...
08/06/2025
Oncology
Quiz
Central Nervous System Progression in Extensive-Stage Small Cell Lung Cancer
03/19/2025
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide...
03/19/2025
Oncology
Quiz
Talazoparib Plus Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
03/05/2025
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the...
03/05/2025
Oncology
Quiz
Lurbinectedin for Patients With Platinum-Sensitive Small Cell Lung Cancer
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology

Recent News

News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
Adding Atezolizumab to Chemoradiation Fails to Improve Outcomes for Limited-Stage SCLC
01/19/2026
Gina Tomaine
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial.
The addition of concurrent and...
01/19/2026
Oncology
News
Berzosertib Plus Topotecan for Patients With Relapsed Platinum-Resistant Small-Cell Lung Cancer: DDRiver SCLC 250 Study
01/15/2026
Gina Tomaine
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results.
Berzosertib plus topotecan did...
01/15/2026
Oncology
News
Prophylactic Tocilizumab May Limit Tarlatamab Toxicities for High-Risk Patients With Extensive-Stage Small Cell and Neuroendocrine Lung Cancer
01/15/2026
Gina Tomaine
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a...
Tarlatamab for patients with...
01/15/2026
Oncology
News
Durvalumab Plus Chemotherapy Shows Real-World Activity in Extensive-Stage SCLC
12/17/2025
Stephanie Holland
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b CANTABRICO trial demonstrate that first-line durvalumab plus platinum-etoposide shows acceptable safety and clinically meaningful survival benefit in extensive-stage small cell lung cancer.
Results from the phase 3b...
12/17/2025
Oncology
News
Adding Pembrolizumab to First-Line Chemotherapy Fails to Improve Survival in Extensive SCLC
12/16/2025
Stephanie Holland
Results from the phase 2 REACTION trial demonstrate that the addition of pembrolizumab to first-line platinum-etoposide does not improve survival among chemo-sensitive patients with extensive small cell lung cancer.
Results from the phase 2 REACTION trial demonstrate that the addition of pembrolizumab to first-line platinum-etoposide does not improve survival among chemo-sensitive patients with extensive small cell lung cancer.
Results from the phase 2...
12/16/2025
Oncology
News
Consolidative Thoracic Radiotherapy Shows Limited Clinical Benefit in Extensive-Stage SCLC
12/10/2025
Stephanie Holland
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 SAKK 15-19 trial, consolidative thoracic radiotherapy after chemoimmunotherapy showed limited clinical benefit for patients with extensive-stage small cell lung cancer.
According to results from the...
12/10/2025
Oncology
News
Escalating Thoracic Radiotherapy Dose May Improve Survival Without Added Toxicity in Limited-Stage Small-Cell Lung Cancer
11/24/2025
Stephanie Holland
Results from a phase 2 study demonstrated that accelerated hyperfractionated thoracic radiotherapy shows favorable long-term efficacy and safety among patients with limited-stage small-cell lung cancer.
Results from a phase 2 study demonstrated that accelerated hyperfractionated thoracic radiotherapy shows favorable long-term efficacy and safety among patients with limited-stage small-cell lung cancer.
Results from a phase 2 study...
11/24/2025
Oncology
FDA Approval
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
11/19/2025
Stephanie Holland
Based on results from the phase 3 DeLLphi-304 trial, the FDA has approved tarlatamab for the treatment of patients with extensive-stage small cell lung cancer who experience disease progression on or after platinum-based chemotherapy.
Based on results from the phase 3 DeLLphi-304 trial, the FDA has approved tarlatamab for the treatment of patients with extensive-stage small cell lung cancer who experience disease progression on or after platinum-based chemotherapy.
Based on results from the phase...
11/19/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use